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Abstract 
The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based 
on their aqueous solubility and intestinal permeability. The BCS Class III compounds are 
hydrophilic molecules (high aqueous solubility) with low permeability across the biological 
membranes. While these compounds are pharmacologically effective, poor absorption due to low 
permeability becomes the rate-limiting step in achieving adequate bioavailability. 
 Several approaches have been explored and utilized for improving the permeability 
profiles of these compounds. The approaches include traditional methods such as prodrugs, 
permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as 
nanoencapsulation and nanosizing. The most recent approaches include a combination/ 
hybridization of one or more traditional approaches to improve drug permeability. While some of 
these approaches have been extremely successful, i.e. drug products utilizing the approach have 
progressed through the USFDA approval for marketing; others require further investigation to be 
applicable. This article discusses the commonly studied approaches for improving the 
permeability of BCS Class III compounds. 
Keywords: Permeability, BCS Class III, Prodrugs, Ion-pairing, Counterion, Nanotechnology, 
Liposome, Permeation enhancer 
  
Introduction 
The Biopharmaceutics Classification System (BCS) of drugs has been developed primarily to 
provide a scientific approach for classifying oral immediate release drug formulations based on 
aqueous solubility and intestinal permeability, in combination with the dissolution properties [1]. 
Pharmaceutical compounds that belong to the BCS Class III are predominantly hydrophilic and 
have a poor permeability profile. This classification can be further extended to include new 
chemical entities (NCEs) with similar properties. Molecules in this class are known to 
demonstrate excellent pharmacological efficacy in-vitro, but present a challenge when 
formulated into orally administered dosage forms due to permeability related issues[2]. Over the 
years, our laboratories have worked with BCS Class III and similar molecules to address 
permeability issues; mainly by prodrug and permeation enhancer based approaches. Besides that, 
researchers have explored several other approaches with an aim to tackle the issue of low drug 
permeability without compromising critical solubility [3, 4, 5, 6, 7]. Among the more commonly 
studied approaches include prodrugs, permeation enhancers, ion-pairing, and other 
nanotechnology-based approaches.  With this review article, we are bringing the foremost 
approaches under one umbrella to help facilitate further research on BCS Class III or analogous 
molecules. 
 This review highlights the different approaches utilized in recent years to increase the 
permeability of BCS Class III compounds. The article is organized such that the more 
established approaches are discussed earlier, followed by the relatively newer approaches. Each 
approach is discussed with respect to its concept, mechanism, advantages/drawbacks, and 
applicability to the oral and non-oral dosage forms. Specific examples of the compounds 
currently being researched, or currently being marketed, are provided as applicable. 
Approaches for improving permeability 
Prodrugs 
Prodrugs have been described earlier as the derivatives of drug molecules that undergo an 
enzymatic or other biochemical transformation in-vivo in order to release its pharmacologically 
active parent drug [8]. The prodrug approaches have been historically utilized for improving the 
physicochemical and pharmacokinetic properties of pharmacologically active agents. Prodrugs 
provide opportunities to overcome several formulation and drug delivery barriers such as poor 
aqueous solubility, physical and chemical instability, insufficient oral absorption, rapid pre-
systemic metabolism, and inadequate tissue permeability [8]. An ideal prodrug is one that is 
readily transported to the desired site, selectively cleaved to release the active drug, and is 
retained at the site of action. 
Improving passive diffusion 
For a majority of drugs, the permeability across cell membranes is known to be significantly 
influenced by their partition coefficient, i.e. their log P value besides other factors like molecular 
size and concentration gradient. Previous reports have hypothesized a sigmoidal relationship 
between the log P value of drugs, and their cell membrane permeability[9]. Therefore, among of 
the more commonly employed prodrug strategies for improving the absorption of poorly 
permeable drugs is to increase the lipophilicity (log P) of drug [10]. Although, the use of log P to 
understand permeability is an over-simplification of the complex process, some correlation exists 
as majority of oral drugs fall between 1-5 log P values. A few outliers with atypical permeability 
behaviors are generally attributed to either active transport, paracellular transport, and/or the 
involvement of other influx-efflux mechanisms. The log P value of drugs can be increased to a 
certain extent by masking the hydrophilic, non-ionizable, or ionizable functional groups such as 
carboxylic, hydroxyl, amine, phosphate, and carbonyl groups. Typically, these functional groups 
are modified into carbonate esters, carbamates, amides, phosphate esters and oximes, which are 
frequently represented in marketed prodrugs. Ester prodrugs are among the most commonly 
designed prodrugs for increasing the lipophilicity, and thus enhancing the passive membrane 
permeability of water-soluble drugs by masking the charged functional groups. Once within the 
physiology, the ester bond is readily hydrolyzed by the esterases found in the blood, liver, 
tissues, and other organs. Figure 1 shows a few of the prominent examples of ester prodrugs 
including, enalapril (ethyl ester), pivampicillin (pivaloyloxymethyl ester), adefovir dipivoxil (a 
diester), and famicilovir (prodrug of penciclovir) [8]. 
 The use of enzymatically labile spacer group moieties is one of the approaches 
researchers have utilized in order to help the drugs resist non-enzymatic hydrolysis during 
passive diffusion. The acyloxyalkyl compounds formed as a result serve as neutral lipophilic 
prodrugs capable of traversing the cell membranes by passive diffusion, followed by intracellular 
reversion to the parent di-acid after the cleavage of acyl group [11]. This is rapidly followed by 
the release of an aldehyde, thereby eliminating the spacer group. Methylene is a standard spacer 
group, owing its popularity to the lack of chirality issues [12]. Researchers have applied this 
approach to synthesize prodrugs for a variety of antiviral agents, including adefovir. 
 Adefovir exists as a di-anionic compound at physiological pH, rendering it extremely 
polar. This highly polar nature of adefovir prevents it from undergoing passive diffusion across 
cellular membranes and intestinal mucosa, thus resulting in poor oral bioavailability. An 
approach for improving  membrane permeability of adefovir involved esterification of the polar 
phosphonic acid group, resulting in a prodrug, adefovir dipivoxil (Figure 1), a compound with 
two pivaloyloxymethyl moieties. The masking of the polar phosphonic acid group resulted in an 
increase in the lipophilicity of adefovir, thereby allowing the prodrug to traverse the cell 
membranes by passive diffusion [11]. The oral bioavailability of adefovir dipivoxil in humans 
was found to be significantly higher (59 %), compared to that of adefovir (12 %) [13]. Besides, 
this prodrug of adefovir demonstrated significantly increased antiviral activity in-vitro, 
indicating increased penetration into infected cells. The clinical (human) safety and efficacy of 
adefovir dipivoxil was later established, and in 2002, an oral tablet formulation (Hepsera®, 
Gilead Sciences, Inc., USA) was approved by the USFDA for the treatment of hepatitis B 
infections. Perioli et al synthesized and evaluated prodrugs of several NSAIDs according to 
the chemical delivery approach developed by Bodor, with a goal to increase their 
permeability across the blood brain barrier (BBB) [14]. The prodrugs were prepared by 
attaching the carboxylic group of NSAIDs to the 1,4-dihydro-1-methylpyridine-3-
carboxylate moiety, which acts as a carrier, via an amino alcohol bridge. The prepared 
prodrugs were found to be promising candidates for improved BBB permeability. 
Improving active transport 
Prodrugs targeted towards specific membrane transporters are designed to have structural 
features that would allow them to be taken up by one of the endogenous transporters present at 
the intestinal epithelium [8]. Targeting specific endogenous transporter is critical for highly 
polar, charged compounds that may not demonstrate passive diffusion as a major absorption 
mechanism. Unlike passive diffusion that is influenced mainly by log P value, active transport of 
drug molecules depends on a wide variety of specific endogenous transporters.  In fact, different 
classes of transporters such as, solute carrier family (SLC) and ATP-binding cassette (ABC) 
transporters have been explored with an aim to increase oral absorption [15]. Transporters such 
as organic cation transporter (OCT), organic anion transporter (OAT), bile acid transporters, 
cholesterol transporter (ABCG5/8), monocarboxylate transporter 1 (MCT-1), etc. have been 
reported in literature to improve oral bioavailability of drugs [16, 17]. 
These transporters are known to have a high transport capacity and a broad substrate specificity.  
A detailed discussion of all transporters is beyond the scope of this article, however readers are 
encouraged to follow the references for detailed information. A few examples are provided to 
illustrate the importance of transporters for increasing the permeability of drug molecules. Well-
known examples of prodrugs that are designed to exploit such transporter-mediated absorption 
include valacyclovir, valganciclovir, and gabapentin. 
Peptide transporters are among the most widely distributed transporters throughout the 
small intestine. Valacyclovir is a l-valyl ester prodrug of acyclovir that is used for the treatment 
of herpes, varicella zoster, and cytomegalovirus (Figure 1). This orally administered prodrug was 
developed to improve the bioavailability of acyclovir, and is a classic example of utilizing the 
carrier-mediated transport. The absolute oral bioavailability of acyclovir (the parent drug) from 
this prodrug was found to be 54.4%, a 3- to 10-fold increase compared to that observed with the 
administration of its parent molecule [18]. The observed increase in the oral bioavailability of 
acyclovir is reported to be the result of favorable transport of valacyclovir into the gut lumen by 
an endogenous oligopeptide transported (PEPT-1) [19, 20, 21].  
 A prodrug approach exploiting the carrier mediated transport was recently explored by 
our laboratory[4]. 4-guanidine oseltamivir carboxylate (GOCarb), Figure 1, is a potential 
influenza treatment that is reported to have a higher potency compared to oseltamivir carboxylate 
(OC). OC was earlier modified to produce an ethyl ester prodrug, which showed significantly 
higher membrane permeability, and was later approved as Tamiflu®. However, emergence of 
resistant strains and the need for better therapeutic outcomes lead us to target GOCarb. Simple 
esterification approach was not successful with GOCarb - a highly polar BCS Class III type 
molecule. A carrier-mediated approach was then used with GOCarb, which involved linking l-
isoleucyl, l-leucyl, or l-valyl with the parent molecule to obtain amino acid prodrugs of GOCarb 
(Figure 1). These prodrugs of GOCarb demonstrated a significant advantage with respect to 
PEPT-1 mediated uptake, increasing its membrane permeability and bioavailability (Figure 2)[4]. 
 Another example involving MCT-1 and sodium dependent multivitamin transporter 
(SMVT) is XP13512, a novel prodrug of gabapentin. The parent drug, gabapentin, is a structural 
analog of γ-aminobutyric acid (GABA) that is currently approved by the USFDA for the 
treatment of epilepsy and post-herpetic neuralgia. This drug is thought to be absorbed from the 
intestines of mammals by a low-capacity solute transporter mainly located in the upper small 
intestine. Due to the saturation of this transporter, gabapentin demonstrates dose-dependent 
pharmacokinetics and high inter-patient variability, i.e. its bioavailability ranges from 30-60% of 
the dose (300 mg) used to treat neuropathic pain [22].  (±) − 1 − {[(𝛼𝛼 − 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖𝑖𝑖) 𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖] 𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖} − 1 −
𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑐𝑐 𝑖𝑖𝑐𝑐𝑖𝑖𝑎𝑎 (XP13512, or gabapentin enacarbil), was later designed to increase 
the absorption of gabapentin throughout the intestine by high-capacity nutrient transporters 
MCT-1 and SMVT. Gabapentin shows no significant interactions with either MCT-1 or SMVT, 
probably due to its charged amine group; however, its prodrug XP13512, combines the 
properties required for recognition by both high-capacity transporters, allowing for its direct 
uptake across human embryonic kidney (HEK) cells [22]. The transcellular flux of XP13512 
across CACO-2 cell monolayers was observed to be five times greater in the apical to basolateral 
direction, further suggesting that the prodrug interacts with both MCT-1 and SMVT. XP13512 is 
rapidly converted to gabapentin in the intestinal and liver tissues of animals and humans. The 
artificial membrane permeability studies at pH 6.5 and 7.4 with XP13512 showed that this 
prodrug may also have some ability to passively diffuse across cell membranes depending on the 
local pH. The 𝑝𝑝𝐾𝐾𝑎𝑎 of XP13512 is 5, suggesting that passive diffusion plays only a minor role, if 
at all, in its intestinal absorption. This prodrug was approved by the USFDA for the treatment of 
Restless Legs Syndrome (RLS) in 2011, and for the treatment of post-herpetic neuralgia in adults 
in 2012. 
 As discussed above, utilizing the active and passive mechanisms of transport have proven 
to be highly successful approaches for improving the permeability, and the overall bioavailability 
of BCS Class III or similar compounds. This can further be extended to address permeability 
issues of BCS Class IV molecules. Among the more popular formulation approaches for 
improving the membrane permeability of these compounds is the use of permeation enhancers. 
The applications of permeation enhancers as a formulation strategy form to increase drug 
permeability are discussed below. 
Permeation enhancers 
Permeation enhancers (PEs), also known as absorption enhancers are chemical moieties included 
in the formulations to facilitate the absorption of drugs from pharmaceutical products. PEs can 
positively influence drug absorption by a variety of mechanisms such as modifying mucus 
rheological properties, altering fluidity of gastric membrane, inhibiting enzymes (e.g. 
proteases) and inhibiting efflux pumps [23]. PEs have been studied for several years in efforts 
to develop non-parenteral formulations for peptides, proteins, and other pharmacologically active 
compounds that have less than optimal membrane permeability [24]. PEs can be useful in 
optimizing drug delivery for oral as well as transdermal/transmucosal (e.g. nasal, buccal, 
sublingual, rectal etc.) absorption sites. However, safety in humans with these agents in always  
a concern and these agents need to be carefully evaluated before they can be approved by FDA. 
This review is limited to the discussions regarding the enhancement of oral absorption of drugs 
with poor permeability. Several PEs currently under investigation are illustrated in Table 1. This 
table also addresses the regulatory status of some of the permeation enhancers with USFDA. 
Most of the research on permeation enhancers is focused on the preclinical evaluation of 
permeability enhancement via in-vitro studies and possible toxicity. 
Table 1: Common permeation enhancers 
Permeation enhancer Proposed mechanism Remarks 
Sodium dodecyl 
sulphate[25] 
Decreases Trans Epithelial 
Electrical Resistance (TEER), 
and facilitates opening of the 
tight junctions 
• Toxicity to the intestinal mucosa 
• Included in the FDA inactive 
ingredients guide (dental preparations; 
oral capsules, suspensions, and tablets; 
topical and vaginal preparations) 
Nα-deoxycholyl-L-lysyl 
methylester[26] 
Increases the lipophilicity of 
drug; drug-complex interacts 
with the bile acid transporter 
and increases absorption 
• Toxicity to the gastrointestinal mucosa 
• Insulin carrier to enhance oral delivery 
 
Rhamnolipids[27] P-gp inhibition 
• Demonstrated to be safe in cell viability 
hemolysis assays 
• Low toxicity, surface active properties 
and antimicrobial activities against 
several microbes (Bacillus cereus, 
Micrococcus luteus, Staphylococcus 
aureus, Listeria monocytogenes) 
thereby showing promising applications 
in pharmaceuticals and therapeutics[28, 
29] 
Phospholipid 
hexadecanol tyloxapol 
(PHT)[9] 
Direct interaction with the 
tight junctions between cells 
resulting in intercellular 
permeation of peptide drugs 
• No significant acute toxicity observed 
in the Lactose dehydrogenase (LDH) 
release assay 
CriticalSorb™ 
(absorption enhancer 
based on Solutol® 
HS15)[30] 
Decrease in TEER; P-gp 
inhibition (combination of 
increased paracellular and 
transcellular flux) 
• No evidence of cytotoxicity in tissue 
histology, and CACO-2 assay 
• Pharmaceutically acceptable excipient 
approved by the FDA as generally 
regarded as safe (GRAS) 
Chitosan[31] 
Opening of the epithelial tight 
junctions (TJ), and paracellular 
transport via translocation of 
JAM-1 (a trans-membrane TJ 
protein) resulting in the 
disruption of TJs 
• No apparent toxicity 
• FDA approved 
D-octaarginine-linked 
polymers[32] 
Polymer induced 
macropinocytosis 
• Polymer-induced uptake is significantly 
suppressed by 5-(N-ethyl-N-isopropyl) 
amiloride, which is an inhibitor of 
micropinocytosis 
• Currently being investigated as a novel 
penetration enhancer[33] 
 
Thiolated 
polyacrylates[2] P-gp inhibition 
FDA approved for topical route (i.e. 
patch, film CR), also shown to improve 
the uptake of hydrophilic macromolecules 
from the GI tract.[34, 35] 
Thiolated 
polycarbophils/ 
glutathione[36] 
Protection against degrading 
enzymes and facilitation of 
transport across intestinal 
membranes 
• Included in the FDA Inactive Database 
(buccal (tablet) and ophthalmic 
(solution) preparations; topical patches; 
vaginal gel)   
• PCP-Cys/GSH system might be a 
promising tool for the oral 
administration of oligonucleotides as it 
allows a significant protection toward 
degrading enzymes and facilitates their 
transport across intestinal 
membranes[37] 
Partially quarternized 
poly(methacrylate) 
terpolymers[38] 
pH-dependent decrease in 
TEER values 
• Reversible decrease in TEER values; 
recovery of cells after 6 hours 
• Partially quarternized poly 
(methacrylate) terpolymers (Q-
BBMCs) have been synthesized, based 
on the basic butylated methacrylate 
copolymer (BBMC/EUDRAGIT E), 
which is an excipient approved by the 
FDA[26]  
Spermine (SPM) - 
polyacrylic acid (PAA) 
polymer ion-pair[39] 
Decreased TEER; paracellular 
permeation via opening of 
tight junctions 
• Polyacrylic acid, sodium salt is listed as 
a food additive by the FDA 
• Cytotoxicity studies in Caco-2 
monolayers revealed the safety of the 
delivery system in the concentration 
range used for permeation 
enhancement.[40] 
• Reversible opening of tight junctions; 
reversible decrease in TEER values 
 
Sodium Caprate[41] 
Opening of tight junctions; 
perturbation of membrane 
lipid or protein 
• Increased intracellular calcium levels to 
induce contraction of calmodulin-
dependent actin filaments 
• FDA approved 
Decanoyl Carnitine[42] 
Opening of tight junctions 
(TJ); perturbation of 
membrane lipid or protein 
Decrease in the intracellular pH and the 
ATP levels. Intracellular acidosis. 
Increases in the calcium levels 
 
 Surfactants are the most frequently utilized wetting agents in pharmaceutical 
formulations for improving the dissolution and absorption of poorly soluble drugs. While 
surfactants are also considered as efficient enhancers, their use in formulations is limited due to 
potential adverse effects on the integrity of the intestinal mucosa. Additionally, they can interact 
with native surfactants (biles acids and phopspholipids) and can have add-on effect. Low 
molecular weight ionic surfactants like sodium dodecyl sulfate (SDS) are among the most 
commonly used classes of compounds for this purpose [43]. SDS has been reported to have 
significant effects on the paracellular permeability in CACO-2 cells by decreasing the TEER 
(Transepithelial electrical resistance) values, increasing the intracellular calcium levels, and 
opening of the tight junctions [25].  
 Gundogdu et al. assessed the effects of SDS in improving the permeability of 
fexofenadine hydrochloride (FEX) using CACO-2 cells.[44] FEX contains a basic amine, and an 
acidic carboxylic acid group, which results in FEX having a pH-dependent aqueous solubility. 
FEX also demonstrates a low, and a concentration-dependent intestinal permeability in CACO-2 
cells in-vitro. Using TEER value as a standard indicator of permeability, the study results 
showed that exposing the cell monolayers to SDS for two hours resulted in a significantly 
increased permeability of FEX. The study also emphasized the importance of TEER value in 
predicting the permeation-enhancing effects of surfactants like SDS. The observed improvement 
in the drug solubilization was attributed to two mechanisms: improvement in the wetting 
characteristics of the drug, and possibly a micellar solubilization of the drug. The CACO-2 
permeability of FEX from the apical to basolateral, and basolateral to apical direction was also 
found to significantly increase with increasing SDS concentration (10 μM - 50 μM). At the 
concentrations assayed, SDS was thought to increase the FEX permeability by relaxing the tight 
junctions while maintaining the integrity of the CACO-2 cell monolayer. 
 𝑁𝑁𝛼𝛼 − 𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑐𝑐ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 − 𝐿𝐿 − 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 − 𝑎𝑎𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖  𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑐𝑐 (DCK) is a permeation enhancer of 
synthetic origin. DCK is composed of a hydrophobic domain from deoxycholic acid, and a 
positively charged lysine that facilitates the ion-pairing interactions with anionic drugs. Such 
ion-pairing interactions could result in an improved absorption of drugs with poor permeability 
profile. DCK is also known to interact with a bile acid transporter in the intestinal membrane that 
could play a role in the enhancement of oral absorption of several drugs. Park et al. investigated 
the influence of DCK as a permeation enhancer on the permeability of ibandronate, a drug used 
in the treatment of osteoporosis [45]. Ibandronate is a highly potent nitrogen-containing 
bisphosphonate with a good safety and a tolerability profile. However, due to its poor absorption 
from the GI tract after oral administration, a relatively high dose (50mg/day, up to 96 weeks) is 
required to be administered to achieve therapeutic effectiveness. Park et al. synthesized 
ibandronate-DCK complex and evaluated the in-vitro permeability, and in-vivo bioavailability of 
the prepared complex in comparison to pure ibandronate in laboratory animals. The in-vitro 
permeability assessment was carried out using a vertical Parallel Artificial Membrane 
Permeability Assay (PAMPA) system. As compared to the parent drug, the prepared 
ibandronate-DCK complex demonstrated a significantly higher permeability of ibandronate, 
suggesting that ionic complexation with DCK can enhance the partition of ibandronate into the 
lipophilic membranes. The amphiphilic nature of DCK was thought to impart lipophilicity to 
ibandronate molecule without any chemical alteration, resulting in the observed increase in its 
absorption.  The prepared ibandronate-DCK complex (1:2) was additionally analyzed for 
bioavailability after intra-jejunal administration in rats. The results showed that the prepared 
ibandronate-DCK complex exhibited 2.8- to 4.3-fold increases in the Cmax and AUC values 
compared to those of pure ibandronate. Thus a significant increase in the relative bioavailability 
of ibandronate due to its complexation with DCK was observed [45]. 
  Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-
glucosamine (de-acetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is a non-toxic, 
biocompatible, and biodegradable polymer, commercially prepared by deacetylation of chitin. 
Chitosan has been shown to be a useful excipient in a variety of drug delivery systems. The 
amine groups present in the polymer have been explored for its role in imparting permeation 
enhancement, controlled release, mucoadhesion, transfection, and inhibition of efflux pumps, etc. 
properties in pharmaceutical dosage forms. In its role as a permeation enhancer, chitosan is 
reported to effectively open the epithelial tight junctions, allowing paracellular transport of the 
compounds via translocation of the junction adhesional molecules [46]. Chitosan is also reported 
to decrease the TEER values of the cell monolayers, and increase the paracellular permeability of 
compounds across them [47, 48]. Additionally, the disruption of the tight junctions by chitosan is 
shown to be a reversible process, ensuring the safety of its use as a permeation enhancer. 
 There are some studies in literature documenting the use of inorganic materials to 
alter physiochemical property of a drug. Literature has shown the use of inorganic 
materials such as layered double hydroxides; Perioli et al prepared hydrotalcite like 
compounds (HTlcs) viz. MgAl-HTlc-FURO to improve furosemide dissolution. The study 
showed that furosemide dissolution was enhanced with these complexes by homogenously 
dispersing the drug and forming a molecular film that could be defined “shell-liquid state”, 
in the nanospaces of the interlayer region [49]. While this study was focused on 
enhancement of drug dissolution, in a later study the authors evaluated the influence of 
these complexes in enhancing the permeability of furosemide [50]. The authors’ main goal 
was to assess gastric mucus rheology and drug flux across gastric mucus layer in vitro. 
They also carried out permeation assays using the artificial membrane (in vitro) and 
porcine gastric mucosa (ex vivo). While the results obtained from artificial membrane did 
not correlate well, the study found a significant increase in furosemide permeability with 
MgAl-HTlc-FURO, when compared to furosemide alone. While this was an interesting 
study demonstrating the use of inorganic materials to enhance bot solubility and 
permeability of a compound, such studies are few and far between, and more inorganic 
compounds such as these need to be explored to understand their influence on the 
mechanistics of drug permeability.       
Current Status of permeation enhancers  
As shown in Table 2, significant advances have been made in the utilization of permeation 
enhancers to improve drug absorption in transdermal formulations, and several transdermal drug 
products using this approach have been approved by the USFDA. While the scientific merit 
regarding the use of this approach in oral formulations has been established in the literature, 
currently no oral drug product is approved for marketing. One of the barriers to the use of 
permeation enhancers in oral formulations is the lack of their established safety profile in 
advanced clinical trials. In recent years, a few drug products utilizing permeation enhancers for 
increasing oral drug delivery are either on the threshold of being approved, or have advanced 
through various stages of clinical trials (Table 2) [24].  
  
 
 
 
Table 2: Permeation enhancers in development/market 
Enhancer/technology Drug/drug product Company 
Cyclopentadecalactone (CPE-
215)[51]  
NasulinTM (nasal 
insulin) 
CPEX Pharmaceuticals, 
Inc. 
Sodium N-[8-(2-
hydroxylbenzoyl)amino] caprylate 
(SNAC)[52] 
Eligen B12TM (oral 
vitamin B12) 
Emisphere Technologies, 
Inc. 
Gipet® (medium chain fatty acids, 
salts, and derivatives)[53] 
Almerol™ (MER-103) 
(alendronate) Merrion Pharmaceuticals 
Sodium caprate[54, 55] Antisense oligonucleotide Ionis Pharmaceuticals, Inc. 
Sodium caprylate[56, 57] Octeotride Chisama, Inc. 
AxcessTM (GRAS excipients)[58] Capsulin
TM (oral 
insulin) Diabetology, Inc. 
(ChiSys®) Chitosan[59] Intranasal apomorphine Archimedes Pharma 
Nexact® - Dodecyl-2-N,N-
dimethylamino propionate 
(DDAIP)[60] 
Femprox® (Topical 
Alprostadil Cream) 
Apricus biosciences, Inc. 
Nexmed (U.S.A.), Inc. 
 
Ion-pairing 
The use of counterions, or ion-pairing method to improve the passive permeability have been 
researched extensively in the past three decades [3, 19, 20, 61, 62]. The ion-pairing approach 
works primarily by complexing the molecule of interest with oppositely charged ionic species, 
resulting in an overall neutral ion-pair that increases lipophilicity, the membrane permeability, 
and the absorption of the molecule [63, 64]. Unlike the prodrug approach where the permeability 
enhancement is achieved via formation of a new chemical entity, the complex formed by ion-
pairing is held together as a single unit by coulombic attractive forces rather than covalent 
bonding [42]. As stated above, the ion-pairing approach works by neutralizing the charge on the 
drug molecules to allow passive diffusion of the ion-pair complex through biological 
membranes. Assuming quasi-equilibrium conditions, this approach would follow the simple rules 
of the association constant as shown in the Figure 3, and equation 1 below, where [BH+] 
represents the drug and [A-] represents the counterion.  
𝐾𝐾 = [𝐵𝐵𝐵𝐵+𝐴𝐴−][𝐵𝐵𝐵𝐵+][𝐴𝐴−]                      (1) 
The common advantages and drawbacks of this approach are summarized in Table 3. 
As shown in this table, a major concern with utilizing the ion-pairing approach for permeability 
enhancement is the possibility of having insufficient and/or weak ionic interaction, which may 
result in the complex dissociating during the absorption phase through the biological membranes. 
This emphasizes the requirement of a high association constant (K) for these interactions. 
Table 3: Advantages and drawbacks of ion-pairing approach 
Advantages Drawbacks 
• Non-prodrug formation of complex; thus 
do not requiring enzymes for activation. 
• Eliminates the necessity of active 
transport for absorption. 
• Complex formed dissociates easily after 
absorption.  
• Equilibrium may be modified to enable 
complex absorption followed by facile 
dissociation of available drug.  
• Additives which may compromise 
membrane integrity, and lead to toxicity 
are not required 
• Possibility of premature complex 
dissociation during membrane permeation 
due to weak non-covalent interactions. 
• Many ion-pairing agents utilized may not 
be suitable for human intake due to known 
membrane irritation and/or toxicity 
challenges. 
• Overutilization of counterions may result 
in the formation of micelles, which may 
exacerbate the poor permeability issues. 
• Concentration-dependent permeability 
enhancement may lead to toxicity at high 
levels 
• Limited range of target partition 
coefficient: the Log P value of the ion-pair 
complex required to be between 2 and 5 to 
facilitate passive membrane permeability. 
Among the more commonly utilized counterion is 1-hydroxy-2-napthoic acid (HNAP).  
This counterion, due to its high lipophilicity, relatively strong binding constant, and a history of 
prior use with drugs such as salmeterol, zanamivir, and oseltamivir makes it an ideal agent to 
counterbalance the high polarity of several BCS Class III drugs [5, 6]. Miller et al. utilized 
HNAP as a counterion to prepare ion-paired complexes of the oral drugs with poor intestinal 
permeability such as zanamivir heptyl ester (ZHE) and guanidine oseltamivir (GO) [6]. The 
study results showed a significant (up to 3.7 log units) increase in the lipophilicity of the drugs 
due to ion-pairing. Furthermore, the study demonstrated the enhancement of permeability by 
plotting a the apparent partition coefficient (Papp) of CACO-2 against the concentration of 
HNAP, and developing a quasi-equilibrium transport model with a linear relationship of the 
slope close to 1. As shown in the Table 4, each formulation may utilize different types of 
counterion approaches to improve permeability.  
 
 
 
  
Table 4: Common ion-pairing agents  
Counterion Counterion type Remarks 
Trifluoroacetic acid 
(TFA)[65] Anionic ion-pairing Reduces the pH of aqueous mobile phase 
Heptafluorobutyric acid 
(HFBA), 
Pentafluoropropionic acid 
(PFPA), phosphoric acid[66] 
Anionic ion-pairing Increases the lipophilicity of the compound 
1-hydroxy-2-napthoic acid 
(HNAP)[6] Anionic ion-pairing 
Increases the partition coefficient (LogP) 
of the compound 
Tetraheptylammonium 
bromide (THAB), 
Tetrabutylammonium iodide 
(TBAI)[67] 
Phase-transfer 
catalyst Increases zeta potential 
Hexadecyldimethylbenzyl 
ammonium chloride, 
Hexylsalicylic acid[38] 
Absorption 
enhancer 
Increased the lipophilicity and 
bioavailability of a beta-lactam 
antibiotic, cefpirom 
 
Although this manuscript is mainly focused on approaches to improve oral permeability, 
these principles can be extended to topical, as well as parenteral formulations. Understanding the 
mechanistic principles of enhanced permeability of a given approach is important, and can help 
extrapolate this information to different routes of administration. A significant amount of ion 
pairing approach is applied to transdermal formulations. Counterions can serve as neutralizing 
agents by binding with the drug molecules via Coulomb forces, reducing their polarity, and 
promoting their transmembrane permeation. The ion-paired complex can then dissociate port-
absorption, permitting drug molecules to diffuse into the epidermal and dermal tissue layers [40, 
68]. Megwa et al. studied the influence of the extent of ion-pairing with alkylamines and 
quaternary ammonium ions on the in-vitro transmembrane permeability of salicylates by 
measuring the conductivity of the penetrant solution [69]. The study showed that an increase in 
the extent of ion-pairing neutralized the overall charge on the molecule, resulting in an increase 
in the flux of the drug across the membrane.  
There are several other examples where counterion approach has increased transdermal 
permeability [70, 71]. There are also reports in literature where the ion-pairing approach have 
been explored for ocular formulations [72]. As mentioned above, exploring approaches utilized 
in non-oral route of administration can assist in identifying counter ions suitable for oral use. 
While studies indicating conceptual success of ion-pairing in improving the permeability of 
drugs are frequently found in scientific literature, additional investigations are required to further 
this concept to clinical trials, resulting in commercially successful products. 
Nanotechnology-based approaches 
In the recent years, nanotechnology based approaches are among the most aggressively 
researched, for enhancing the delivery of pharmaceutical drug formulations. Due to the perceived 
advantage of small particle size (≤100nm) in increasing transmembrane permeability, 
nanotechnology based products are presumed to provide a significant improvement in the 
bioavailability of several drugs [73]. Several studies have been reported that link the bio-
toxicity of nanoparticles to their small particle size. However, more comprehensive studies 
have shown that nanoparticle-induced bio-toxicities are a result of a complex interplay of 
the size, shape, surface chemistry, and the charge on the particles [74]. This review is 
focused purely on the merits of nanotechnology in aiding the drug permeability and 
bioavailability. The section below discusses current advances in the use of nanotechnology-
based approaches for the improvement of drug permeability, and their overall bioavailability. 
Nanoparticles  
The use of nanoparticles for increasing the permeability of drugs has been a subject of current 
scientific and biomedical research. Originally stemmed from the focus of delivering anti-cancer 
agents, this approach has gained popularity due to its reported ability to allow delivery of nucleic 
acids, peptides, etc. for the treatment of several diseases [75]. The emergence of this approach 
also stems from the drawbacks associated with the therapeutic interventions using 
macromolecules or micromolecules. Most macromolecular drugs are reported to have a high risk 
of proteolytic and/or hydrolytic degradation, resulting in low bioavailability and a shorter half-
life. Micromolecular anticancer drugs are associated with toxic side effects or unsuitable bio-
distribution [75]. Additionally, small-molecule anticancer agents may quite often be hydrophilic 
in nature, and suffer from poor permeability similar to that observed with BCS Class III drugs. 
Thus, the primary aim of the nanoparticle-based approaches is to improve the permeability 
profiles of drugs, in addition to preventing the undesired side effects. 
 The nanoparticle based approach works by encapsulating the drug molecule in polymeric 
nanoparticles with a goal to overcome several challenges such as hydrophilicity, poor cellular 
penetration due to size, biological degradation, and toxicity of the drug molecules [75]. In 
addition, the significant reduction of the particle size to ≤100 nm is known to result in dramatic 
changes in the pharmacokinetics of the drug molecules, particularly the drugs’ permeability and 
delivery efficiency [31]. Since low permeability is the greatest challenge for drugs in BCS Class 
III, the nanoparticle based approach provides a promising new direction for formulating these 
drugs. Nanoparticle based formulation of drugs can be achieved in several ways, i.e. entrapment 
of drug molecules in polymeric nanoparticles, adsorption of drug molecules on the surface of 
nanospheres, or formulation of aqueous-core nanocapsules. Table 5 summarizes some of the 
advantages and drawbacks of each of these approaches[7]. 
Nanoparticle-based formulations offer several advantages. First, drug encapsulation 
prevents biological macromolecules from degradation in the GI tract, and allows them to reach 
the target site in relatively higher concentration. Second, encapsulation may increase the oral 
bioavailability of these drugs while minimizing the plasma concentration fluctuations and the 
systemic side effects. This is due to the utilization by the nanoparticles, of different uptake 
mechanisms such as ‘active transport system’ or ‘endocytosis’, and the ability of the drug to 
remain in circulation for a prolonged period of time, mimicking a controlled-release profile. 
Third, nano-encapsulating drug molecules significantly decreases the size, allowing more passive 
diffusion, and penetration through the biological membranes. The uptake of nanostructures has 
been reported to be about 15-250 times greater than that of microparticles in the 1-10 μm range 
[31]. 
Table 5: Nanoparticle-based formulation strategies 
Strategy Advantages Drawbacks 
Entrapment in 
polymer 
nanoparticles 
• Drug protection 
• Sustained drug release 
• Loading efficiency dependent 
on the formulation process 
• Lack of drug solubility in polymer 
• Reaction between drug and PACA/monomer 
• Use of organic solvent 
• Medium acidification during polyester 
degradation 
• Rapid degradation of alginate nanoparticles 
by cation exchange 
Adsorption 
onto polymer 
nanoparticles 
• Drug not submitted to the 
formulation process 
• Nature of polymer (charge, 
hydrophilicity) influences drug 
loading 
• No reaction between drug and 
polymer  possibility of 
modifying the nanoparticle 
surface 
• Drug leakage and rapid release 
• Nanoparticle destabilization by charge mask 
• Stealth properties modified 
• Lower biological efficacy 
• Use of organic solvent 
Entrapment in 
Aqueous Core 
Nanoparticles 
(ACN) -drug 
protection 
• Drug solubilized in the core 
• Reaction between drug and 
monomer is limited 
• Low polymer content 
• Sustained drug release 
• High energy devices for generating 
emulsions and nano-emulsions 
• Organic solvent 
 
Several agents belonging to different chemical classes have been explored for their use as 
nano-encapsulating agents. These chemical classes with their unique attributes, and current 
status of some specific examples are summarized in Table 6; enlisting all the examples and 
their current statuses is beyond the scope of this review. Nanoparticulating or nanosizing of 
drugs involves a reduction of drug particle sizes to less than 100 nm. Nanoparticulation of drug 
particles have been reported to provide several advantages including enhanced drug delivery, 
reduction in the amount of expensive Active Pharmaceutical Ingredient (API) required, 
protection from biological degradation, and possible achievement of higher specificity with 
minimized side effects. Among the popular nanoparticulating techniques are formulation of 
liposomes, and the use of nanometric carriers, each with their unique contribution in enhancing 
drug delivery via an increase in permeability [27]. 
Table 6: Nanoparticle encapsulation agents 
Category Examples Toxicity  Current status Comments 
Polymer based agents 
Polymer-drug 
conjugates 
 
 
Natural polymers: 
• albumin, 
chitosan, and 
heparin 
 
Synthetic polymers: 
• N-(2-
hydroxypropyl)-
methacrylamide 
copolymer 
(HPMA) 
• Nontoxic and 
biodegradable 
• Paclitaxel-
albumin 
(Abraxane® 
Approved by 
the USFDA 
in 2005 for 
the 
treatment of 
breast, lung, 
pancreatic, 
and small 
cell lung 
• Synthetic or 
natural 
• Water-soluble 
• Selective drug 
accumulation 
in tumor tissue 
(EPR effect) 
• Receptor-
mediated 
targeting to 
increase 
specificity 
• Polystyrene-
maleic anhydride 
copolymer 
• Polyethylene 
glycol (PEG) 
• Poly-L-glutamic 
acid (PGA) 
cancers [76, 
77] 
• Doxorubicin-
HPMA 
copolymer 
(Phase II 
trials 
completed) 
[78] 
• Paclitaxel-
Poly 
(glutamic 
acid) (Phase 
II trials 
completed) 
[79] 
• PEG-Pglu 
(SN38) 
(Phase II 
trials for 
breast 
cancer) [80, 
81] 
toward cancer 
cells 
Polymeric 
micelles 
 
 
• Paclitaxel 
• Genexol-PM 
(PEG-poly(D,L-
lactide)-
paclitaxel) 
• Biodegradabl
e and non-
toxic 
• Paclical 
(Paclitaxel 
polymeric 
micelle)( 
Phase III 
completed 
for ovarian 
cancer) [82] 
• Amphiphilic 
block 
copolymers 
• Suitable 
carrier for 
water-
insoluble 
drugs 
• Biocompatible
, self-
assembling 
• Ease of 
modification 
• Targeting 
potential 
Dendrimers 
 
  
• Poly(amidoamin
e) 
• Cationic 
dendrimers 
exhibit 
hemolytic 
toxicity, 
cytotoxicity 
and 
hematologica
l toxicity[83] 
• Neutral and 
negatively 
charged 
• Docetaxel-
dendrimer 
conjugate 
(DEPTM-
Docetaxel in 
Phase I 
trials for 
advanced 
metastatic 
cancer)[84] 
• Synthetic 
polymeric 
macromolecul
e with 
nanometer 
dimensions 
• Monodisperse 
size, 
modifiable 
surface 
functionality 
 high 
dendrimers 
are non-
toxic[83] 
structural and 
chemical 
homogeneity 
• Multivalency 
• Water 
solubility and 
biodistribution 
can be 
modified 
• Internal cavity 
• Controlled 
degradation 
Lipid based agents 
Liposomes 
 
 
• Pegylated 
liposomes 
• Non-pegylated 
liposomes 
• Cationic 
liposomes 
(non-
pegylated 
liposomes) 
has shown to 
cause dose 
dependent 
toxicity and 
pulmonary 
inflammation 
in mice[85] 
• Doxil 
(Doxorubici
n liposomes 
approved 
for the 
treatment of 
Kaposi’s 
sarcoma, 
ovarian 
cancer and 
breast 
cancer)[86, 
87]  
• Amphiphilic, 
biocompatible 
• Ease of 
modification 
• Targeting 
potential 
Viral 
nanoparticles 
 
 
• Cowpea mosaic 
virus 
• Cowpea chlorotic 
mottle virus 
• Canine 
parvovirus 
• Bacteriophages 
• Could elicit 
immune 
response in 
host[88] 
• Cowpea 
mosaic virus 
is reported to 
be safe [89] 
• Viral 
nanoparticles 
containing 
iron oxide 
are reported 
to be 
toxic[90] 
• Emerging 
field with 
applications 
in disease 
prevention, 
diagnosis, 
monitoring 
and 
therapy[91] 
• Multifunction
al with 
specific tumor 
targeting  
• Multivalency 
– ability to 
allow various 
surface 
modifications 
• Defined 
geometry and 
uniformity 
• Biological 
compatibility 
and inert 
nature 
Carbon 
nanotubes 
 
 
- 
• Reported to 
have multiple 
toxicities 
depending on 
the surface 
charge, 
shape, length, 
diameter, 
• Emerging 
area of 
research • Use of 
benzene ring 
• Multifunction
al 
agglomeratio
n and 
purity[91, 92] 
 
Liposomes and other nanometric carriers 
Liposomes are generally described as lipid-based microscopic vesicles with sizes ranging from 
50 nm to over 100μm. Liposomes may possess a negative, positive, or a neutral surface-charge 
depending on their composition. In addition, depending on their size, liposomes may be 
categorized as unilamellar vesicles, or in the presence of more than one bilayers, multilamellar 
vesicles [93]. The lipid bilayers of the liposomes possess both hydrophilic and lipophilic 
properties, similar to that observed in the phospholipid bilayer in human cells. These properties 
provides liposomes with a specific advantage with respect to increasing permeability by 
facilitating enhanced interactions between the drug and the cell membrane. Enhanced 
permeability with liposomes is achieved via one or more of the four mechanisms: adsorption, 
endocytosis, fusion, and lipid transfer. Additionally, derivatized liposomes such as pegylated 
liposomes have been reported to display a prolonged drug circulation, and a slower release of 
drug molecules similar to controlled-release formulations [94, 95]. Liposomes are also reported 
to possess the ability to provide target-site specificity, as demonstrated by pegylated horse-
radish-peroxidase loaded liposomes targeting the brain capillary endothelial cells [96].    
Another nanotechnology-based approach for permeability enhancement of drugs is the 
use of nanometric carriers. This approach involves adsorbing, entrapping, or covalently attaching 
the drug molecules to sub-micron sized particulate carriers in an attempt to improve the drug 
permeability.  Among the reported advantages of this approach are, ease of passage across even 
the smallest of the capillary vessels, achievement of higher penetration into the cells and organs, 
prolonged plasma circulation by avoiding phagocytic clearance, improved therapeutic effects of 
drugs, and the ease of functional modifications for improving stability [31]. Current research 
with regards to utilizing this approach for enhanced drug delivery is primarily focused on 
achieving target specificity, improving the drug delivery capacity, and the use of a combination 
of carrier materials to improve drug delivery efficiency. Among the commonly employed 
nanometric carrier materials include, poly-lactic acid (PLA), poly-glycolic acid (PGA), and poly-
lactide-coglycolide (PLGA).  
Smart drug delivery systems, polymer-drug conjugates, and multifunctional carrier systems 
Achieving acceptable drug permeation and accumulation in the target tissue or organ calls for 
designing a drug delivery system that is multifunctional, and more specifically possessing a 
property of switching ‘on’ or ‘off’ certain functions when required [31]. While several attempts 
have been made to formulate such a drug delivery system utilizing nanotechnology based 
approaches such as liposomes or nanoparticles, only few successes have been reported [97].  
 The Smart Drug Delivery Systems (SDDS), also known as the stimuli-sensitive delivery 
systems function on a principle of ‘rapid transition of the physical-chemical properties of a 
polymer system upon contact with a stimulus’, the stimulus being either physical, chemical, or 
biological, to trigger a desired drug release [31]. A commonly employed approach for the 
development of SDDS is through the use of polymer micelles. The polymeric micelles contain 
both hydrophilic, and lipophilic domains, and when used to encapsulate hydrophilic drugs, are 
known to increase the permeability via passive diffusion. The release of drug occurs upon the 
degradation of the micellar domains in-vivo. A specific example of micelle forming polymeric 
agent is Poly (ethylene glycol)-b-polyhistidine (PEG-b-PHis). A unique property of PEG-b-PHis 
is the ability to adjust its pKa by changing its molecular weight. Several studies report successful 
utilization of PEG-b-PHis to prepare SDDS, and achieve targeted and controlled drug delivery 
[98, 99]. Higher localized drug accumulation have been achieved at the desired target site even 
with the parenteral administration of SDDS [100]. Chu et al. prepared a SDDS which consisted 
of a glucose-sensitive microcapsule with a porous membrane, with linear-grafted polyacrylic 
acid (PAAC) chains, and covalently bound glucose oxidase enzymes in the membrane pores 
acting as functional gates [101]. The study results showed that the prepared SDDS provided a 
self-regulated drug delivery systems capable of releasing insulin in response to changes in the 
plasma glucose concentration. 
 The polymer-drug conjugates has been a successfully utilized approach for improving the 
delivery of several drugs. However, this approach is mainly employed to improve the 
solubilization of drugs, rather than for improving permeability. Polymer-drug conjugates 
typically consists of water-soluble polymers that attach to the drug molecules, forming a 
conjugate with increased aqueous solubility and distribution. An advantage of utilizing polymer-
drug conjugates is the formation of colloidal particles which may prolong the drug circulation 
time [31]. Multifunctional drug delivery systems (MDDS) are the systems that possess more than 
one of the functional properties observed with the nanotechnology based approaches. These 
delivery systems exhibit properties such as stimuli-sensitivity, passive/active drug localization at 
targeted site, ability to achieve higher bioavailability, and/or increased blood circulation time. An 
example of a MDDS would be a mixture of PLA-b-PEG-b-PHis-biotin and PEG-b-PHis block 
copolymers [68]. 
 Nanotechnology-based approaches provides a plethora of options for enhancing drug 
delivery via different routes, i.e. oral, parenteral, pulmonary, topical etc. Although parenteral 
formulations are devoid of challenges related to drug permeability (since they are directly 
injected into blood stream), it is still important to evaluate the benefits of using nanoparticle 
based formulations to ensure the distribution/bioavailability of the drug at the site of action. Zara 
et al. compared the pharmacokinetics of doxorubicin incorporated as ion-pair into Solid-Lipid 
Nanospheres (SLN) with that of the commercial solution of the drug in laboratory animals [102]. 
They observed that SLN showed a markedly higher concentration of doxorubicin in the blood, 
lung, spleen, and brain, at each time point than observed with the commercial solution. The study 
also found that the SLN-treated rats showed a lower doxorubicin concentration in liver, heart and 
kidney. Additionally, the results showed that SLN increased the area under the curve (AUC) of 
doxorubicin compared to a conventional doxorubicin solution. Since oral administration is the 
most preferred route of administration, it is also the focus of several nanotechnology-based 
studies for improving drug bioavailability. Kalaria et al. prepared and pharmacokinetically 
evaluated doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles [103]. They 
found that the doxorubicin-loaded nanoparticles demonstrated a significant (363%) increase in 
the bioavailability of doxorubicin, and a six fold increase in its Tmax.  
 Pulmonary drug delivery is another area that has benefitted from nanotechnology based 
approaches. Here, however, a nanoparticulate strategy via micronization of drug particles rather 
than drug encapsulation is utilized. Smaller drug sizes enable better penetration in the lung either 
via i.v. administration (through microspheres), nebulized solutions, or dry powder inhalations. 
An example of nanoparticle utilization for pulmonary administration is the microemulsion 
system based on water/lecithin/propanol/iso-octane [104]. The small size of nanoparticles allows 
them to be the ideal candidates for pulmonary administration. However, the effects of 
microsizing/nanosizing on the manufacturability, stability, and the safety of the drug products 
need further research and analysis. Due to the small size and higher penetration observed with 
nanotechnology based products, nanoparticles have also found applications in topically 
administered products. In comparison to the conventional drug molecules, nanoparticles result in 
a more unison drug particle and larger number of particles, leading to a higher occlusion factor 
and skin penetration (Figure 4).  Moreover, compared to conventional formulations, a smaller 
dose is required with nanoparticles. This results in a significant reduction in the occurrence of 
irritation, dryness, itching, and/or burning sensation that can occur with conventional dosage 
forms.  
 A promising new application of nanoparticles is the possibility of achieving a target 
specific drug delivery. Gao et al. investigated the multivalent effect for up-regulating the 
intracerebral delivery of nanoparticles via receptor-mediated transcytosis [105]. They prepared 
nanoparticles labeled with near-infrared (NIR) fluorophore and different numbers of angiopep-2 
peptides that specifically target low-density lipoprotein receptor-related protein (LRP) on the 
blood brain barrier (BBB). The in-vivo NIR image analysis showed that the multimetric 
association between the angiopep-2 peptides labeled on the nanoparticle, and the LRP receptors 
on the BBB significantly increased the intracerebral uptake of the nanoparticles. 
Hybrid or combination approaches 
With the advancement of technology, several studies employing a combination of one or more 
approaches above to improve drug permeability have been explored. Fattal et al. studies the 
effect of hybridization of polyalkylcynoacrylate nanoparticle and an ion-pairing agent, cation 
hydrophobic detergent (CTAB) on the delivery of antisense oligonucleotides (ON) in modulating 
gene expression [106]. ON was loaded into the polyalkylcyanoacrylate nanoparticle that was 
formed via an emulsion polymerization process. The obtained complex was then coated with 
CTAB to create a lipophilic nanoparticle-ion paired complex. The functional characterization of 
this complex was then carried out via in-vitro and in-vivo analysis. The in vitro analysis showed 
an increase in the cellular uptake of the drug complex, as it survives the nuclease attack in the 
cell culture media and is actively taken up via the endocytotic/phagocytotic pathway.  The in-
vivo analysis demonstrated an increased stability of the drug complex in plasma and liver. While 
this method of hybridization between nanoparticle and the ion-pairing approach did not 
demonstrate an increased drug permeability, and instead increased the active uptake of the drug, 
it is still a feasible method to consider.  
 Another example of hybridization/combination of nanoparticle and ion-pairing approach 
is the formation of an insulin-sodium deoxycholate complex with an aim to promote the oral 
delivery of insulin [41]. In this study, an insulin-deoxycholate complex (Ins-SD-Comp) was first 
formed by the hydrophobic ion-pairing method to increase the lipophilicity of insulin. This 
complex was also hypothesized to enhance the bioavailability of insulin, as sodium deoxycholate 
is naturally produced by the liver and undergoes enterohepatic circulation up to 20 times a day. 
This Ins-SD-Comp was then encapsulated in poly (lactide-co-glycolide) (PLGA) nanoparticle via 
emulsion solvent diffusion method to form Ins-SD-Comp-PLGA-NP, to prevent physiological 
degradation and enable oral administration. The hypoglycemic effects of this hybrid complex 
were analyzed by the in vivo bioassay. The results showed that this hybrid complex demonstrated 
a statistically significant plasma glucose reduction when compared to oral administration of 
saline-free insulin solution.  
Conclusions 
GI absorption of the low permeability compounds such as those belonging to the BCS Class III 
or molecules with similar properties is an area of extensive research. For these drugs, the 
intestinal membrane permeability is expected to be the rate-limiting step in the overall drug 
absorption process. Amongst the various approaches used for improving the permeability 
include, prodrugs, permeation enhancers, ion-pairing, and nanotechnology based approaches. 
 The use of prodrugs or targeting carrier-mediated transport has proven to be a relatively 
successful in improving the permeability. Ion-pairing approach has yielded positive results in 
transdermal and parenteral drug delivery; however, further research for the application of this 
approach for oral delivery is still underway.  
 Nanotechnology-based approach have shown to provide a promising technology to 
enhance the permeability of the drugs. Both the nanoencapsulation and nanosizing strategies 
result in significant reduction in the particle size, resulting in improved drug permeability. While 
the majority of research utilizing nanotechnology is still under clinical trials, the current results 
from different routes of administration have demonstrated positive outcomes. Similar to ion-
pairing approach, further research is required to assess the safety profile of nanotechnology-
based products and the ease of their manufacturing. Once thought impossible, the hybridization 
of several approaches for improving drug permeability is now feasible. While the initial studies 
have demonstrated a success in the formation of nanoparticle-ion-paired hybrid complexes and 
stable activity, it is usually either the ion-pairing effect or the nanoparticle effect that is found to 
be the key permeability enhancer. Nonetheless, further advancement in the technology and 
refinement of approaches will certainly make the hybrid-complexes a successful strategy in 
improving drug permeability. 
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